PDCD1 and hepatocellular carcinoma: A recent clinical trial demonstrated that lenvatinib plus anti‐PD‐1 antibodies is effective and safety conversion therapy regimen for unresectable HCC, and the responders showed significant enrichment of CD8+ T cells.[22] Banta et al.